ES2493591T3 - Procedimiento para obtener compuestos de fosfato esteroideos - Google Patents

Procedimiento para obtener compuestos de fosfato esteroideos Download PDF

Info

Publication number
ES2493591T3
ES2493591T3 ES08750640.8T ES08750640T ES2493591T3 ES 2493591 T3 ES2493591 T3 ES 2493591T3 ES 08750640 T ES08750640 T ES 08750640T ES 2493591 T3 ES2493591 T3 ES 2493591T3
Authority
ES
Spain
Prior art keywords
phosphate compounds
procedure
formula
steroidal
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08750640.8T
Other languages
English (en)
Inventor
Luis Sobral
Filipe Gaspar
William Heggie
Emilia Leitao
Jose Refael Antunes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hovione Inter AG
Original Assignee
Hovione Inter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hovione Inter AG filed Critical Hovione Inter AG
Application granted granted Critical
Publication of ES2493591T3 publication Critical patent/ES2493591T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Un procedimiento para obtener compuestos 21-fosfato disódico esteroideos de fórmula [I], donde X>=R>=H, o X>=F y R>=a-CH3, o X>=F y R>=b-CH3**Fórmula** comprendiendo el procedimiento el secado por aspersión de una solución que contiene un compuesto de fórmula [I], donde la concentración del compuesto de fórmula [I] en la solución es del 2 % (p/p) al 30 % (p/p), donde la solución es secada por aspersión a una temperatura de 65 °C a 105 °C y donde el pH de la solución es de 7,6 a 9.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
ES08750640.8T 2007-05-16 2008-05-16 Procedimiento para obtener compuestos de fosfato esteroideos Active ES2493591T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT10374307 2007-05-16
PT103743A PT103743B (pt) 2007-05-16 2007-05-16 Processo para preparar derivados de 21-disódio fosfato de pregnanos.
PCT/GB2008/001709 WO2008139210A2 (en) 2007-05-16 2008-05-16 Process for obtaining steroidal phosphate compounds

Publications (1)

Publication Number Publication Date
ES2493591T3 true ES2493591T3 (es) 2014-09-12

Family

ID=39643770

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08750640.8T Active ES2493591T3 (es) 2007-05-16 2008-05-16 Procedimiento para obtener compuestos de fosfato esteroideos

Country Status (8)

Country Link
US (1) US8445471B2 (es)
EP (1) EP2148657B1 (es)
JP (1) JP5631203B2 (es)
CN (1) CN101742987B (es)
ES (1) ES2493591T3 (es)
IL (1) IL202171A (es)
PT (1) PT103743B (es)
WO (1) WO2008139210A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105294810A (zh) * 2014-07-16 2016-02-03 河南利华制药有限公司 一种高标准泼尼松龙磷酸钠的生产工艺
CN109988212B (zh) * 2019-04-22 2020-11-20 河南利华制药有限公司 一种泼尼松龙磷酸钠生产方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2936313A (en) * 1957-11-19 1960-05-10 Glaxo Lab Ltd Preparation of steroidal 21-phosphate derivatives
DE1134075B (de) * 1959-11-26 1962-08-02 Merck Ag E Verfahren zur Herstellung von primaeren Steroid-21-orthophosphorsaeureestern und deren physiologisch vertraeglichen wasserloeslichen Salzen
US3966778A (en) * 1965-05-08 1976-06-29 Takeda Chemical Industries, Ltd. Production of 21-phosphate corticords having unprotected hydroxyl radicals at least at the 17α- and 21-position
GB1133553A (en) * 1967-04-05 1968-11-13 Merck & Co Inc Inhalation aerosol composition
FR2525108B1 (fr) * 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
JPH09301851A (ja) * 1996-05-17 1997-11-25 Fuji Chem Ind Co Ltd 圧縮成形性に優れた結晶性薬物粒子及び該化合物の製造方法
ATE312601T1 (de) * 1999-05-27 2005-12-15 Acusphere Inc Poröse arzneistoffmatrizen und deren herstellungsverfahren
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
CN1951388A (zh) * 2005-10-18 2007-04-25 李文宁 注射用倍他米松磷酸钠粉针剂及制备方法

Also Published As

Publication number Publication date
WO2008139210A2 (en) 2008-11-20
PT103743A (pt) 2008-11-17
JP2010526860A (ja) 2010-08-05
JP5631203B2 (ja) 2014-11-26
CN101742987A (zh) 2010-06-16
WO2008139210A3 (en) 2009-04-16
EP2148657B1 (en) 2014-06-04
IL202171A (en) 2015-08-31
CN101742987B (zh) 2015-07-22
US8445471B2 (en) 2013-05-21
PT103743B (pt) 2013-01-15
US20100240916A1 (en) 2010-09-23
EP2148657A2 (en) 2010-02-03
IL202171A0 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
ES2575565T3 (es) Procedimiento para la preparación de monohidrato de treprostinilo y su utilización para el almacenamiento y el envío
CL2022003434A1 (es) Compuestos para tratar la enfermedad de huntington (divisional solicitud 202003378)
MX2022013974A (es) Inhibidor de sos1 que contiene fosforo.
ES2532948T3 (es) Composición tópica para el tratamiento de queratosis actínica
BR0116369A (pt) Composto, método para a profilaxia ou o tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, uso de um composto, e, processo para preparar composto
ECSP099571A (es) Derivados pirazólicos como inhibidores de la 11-beta-hsd1
CL2009000870A1 (es) Compuestos derivados de acidos p-1,3,4-oxadiazolil-2-il-fenilboronicos, inhibidores de amida hidrolasa de acido graso (faah); composicion farmaceutica, utiles para tratar una afeccion, enfermedad o trastorno doloroso, inflamatorio, inmunologico, entre otros.
CR10937A (es) Inhibidores de cinasa mapk/erk
UY30004A1 (es) Metodos y kits para dosificar nucléosidos antivirales beta-d-2´, 3´-didehidro-2´, 3´- dideoxi-5-fluorocitidina
BRPI0415760A (pt) derivados de benzimidazolila
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
CL2007003491A1 (es) Forma cristalina del acido (3s)-3-[n-(n-(2-tercbutilfenil)oxamil)alaninil]amino-5(23,5,6-tetrafluorofenoxi)-4-oxopentanoico; composicion farmaceutica que comprende a dicho compuesto; y su uso para tratar la fibrosis hepatica.
BRPI0911161B8 (pt) derivados de piridazinona e seu processo de preparação
EA201100966A1 (ru) Производные пиридазинона
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
AR061901A1 (es) Proceso para la produccion de fosfatos metalicos nanofinos, fosfato nanofino producido mediante dicho proceso y su uso
BRPI0712889A8 (pt) composto, processo para a preparação de um composto, composto intermediário, e, composição farmacêutica.
UY26256A1 (es) Amidas de ácidos carboxílicos, medicamentos que contienen estos compuestos, su utilización y su preparación
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
ECSP099351A (es) Compuestos heterociclicos y su uso como inhibidores de la
BRPI0713457A2 (pt) composto, uso do mesmo, composição farmacêutica, método de tratamento de arritmias, agente para o tratamento de arritmias, e, processo para preparar um composto
CO6331380A2 (es) Proceso de calcinacion bajo en fibra para la fabricacion de tableros de fibra de yeso
ES2493591T3 (es) Procedimiento para obtener compuestos de fosfato esteroideos
BRPI0607330A2 (pt) composto, processo para preparar o mesmo, composição farmacêutica, método para tratar inflamação ou prevenir apoptose em um indivìduo, e, uso do composto
CO2024000054A2 (es) Forma cristalina de tolebrutinib y método de preparación y su uso